PriceTargets.com logo

TransMedics Group - TMDX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $53.29
  • Forecasted Upside: -22.85%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$69.07 As of 01/27/2023 01:00 AM ET
▲ +2.94 (4.45%)

This chart shows the closing price for TMDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TransMedics Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMDX

Analyst Price Target is $53.29
▼ -22.85% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $53.29, with a high forecast of $70.00 and a low forecast of $39.00. The average price target represents a -22.85% upside from the last price of $69.07.

This chart shows the closing price for TMDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in TransMedics Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2023Morgan StanleyBoost TargetEqual Weight$54.00 ➝ $63.00Low
12/16/2022CowenBoost Target$60.00 ➝ $70.00Low
11/4/2022Morgan StanleyBoost TargetEqual Weight$45.00 ➝ $54.00Low
11/4/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$58.00 ➝ $63.00Low
10/11/2022Morgan StanleyBoost TargetEqual Weight$37.00 ➝ $45.00Low
8/4/2022Canaccord Genuity GroupBoost Target$46.00 ➝ $58.00Low
8/3/2022Morgan StanleyBoost TargetEqual Weight$34.00 ➝ $37.00Low
8/2/2022OppenheimerBoost TargetOutperform$40.00 ➝ $45.00Low
8/2/2022CowenBoost Target$45.00 ➝ $50.00Low
8/2/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$26.00 ➝ $48.00Low
7/26/2022CowenBoost TargetOutperform$39.00 ➝ $45.00Low
6/29/2022Morgan StanleyBoost TargetEqual Weight$25.00 ➝ $34.00Low
6/28/2022CowenBoost TargetOutperform$35.00 ➝ $39.00Low
5/4/2022Canaccord Genuity GroupBoost Target$39.00 ➝ $46.00High
5/4/2022CowenBoost Target$28.00 ➝ $35.00High
3/17/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$38.00 ➝ $39.00High
3/17/2022Canaccord Genuity GroupBoost TargetBuy$38.00 ➝ $39.00High
2/25/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $15.00High
2/25/2022Canaccord Genuity GroupLower Target$79.00 ➝ $38.00High
2/24/2022JPMorgan Chase & Co.Lower Target$20.00 ➝ $12.00High
1/7/2022Morgan StanleyLower TargetEqual Weight$33.00 ➝ $22.00High
10/14/2021JPMorgan Chase & Co.Boost TargetNeutral$29.00 ➝ $30.00Low
10/8/2021CowenLower TargetOutperform$49.00 ➝ $39.00High
7/8/2021OppenheimerInitiated CoverageBuy$49.00Medium
6/18/2021CowenReiterated RatingBuy$49.00High
5/5/2021Morgan StanleyLower TargetEqual Weight$38.00 ➝ $35.00High
3/29/2021CowenBoost TargetPositive ➝ Outperform$44.00 ➝ $49.00Low
3/3/2021Morgan StanleyBoost TargetEqual Weight$16.00 ➝ $38.00High
3/2/2021OppenheimerBoost TargetHold ➝ Outperform$25.00 ➝ $40.00High
2/24/2021CowenBoost TargetOutperform$20.00 ➝ $44.00High
11/6/2020Morgan StanleyLower TargetEqual Weight$18.00 ➝ $16.00Low
11/5/2020OppenheimerReiterated RatingBuy$25.00High
10/8/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$15.00Low
8/7/2020Morgan StanleyBoost TargetEqual Weight$15.00 ➝ $18.00Medium
8/6/2020OppenheimerReiterated RatingBuy$25.00High
7/1/2020OppenheimerInitiated CoverageBuy$25.00Low
5/6/2020OppenheimerReiterated RatingBuy$25.00High
4/19/2020OppenheimerInitiated CoverageOutperform$25.00Medium
4/6/2020OppenheimerInitiated CoverageOutperform$25.00High
3/4/2020Morgan StanleyLower TargetEqual Weight$22.00 ➝ $16.00Medium
11/7/2019CowenLower TargetOutperform$40.00 ➝ $28.00High
5/28/2019Morgan StanleyInitiated CoverageEqual ➝ Equal WeightHigh
5/28/2019JPMorgan Chase & Co.Initiated CoverageOverweight$34.00High
5/28/2019CowenInitiated CoverageOutperform ➝ Outperform$40.00High
(Data available from 1/28/2018 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/1/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/31/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2022
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/29/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/29/2022
  • 7 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2023

Current Sentiment

  • 7 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

TransMedics Group logo
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
Read More

Today's Range

Now: $69.07
Low: $66.02
High: $69.09

50 Day Range

MA: $60.25
Low: $53.63
High: $69.07

52 Week Range

Now: $69.07
Low: $10.00
High: $69.09

Volume

305,291 shs

Average Volume

292,775 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of TransMedics Group?

The following Wall Street research analysts have issued stock ratings on TransMedics Group in the last year: Canaccord Genuity Group Inc., Cowen Inc, Cowen Inc., JPMorgan Chase & Co., Morgan Stanley, and Oppenheimer Holdings Inc..
View the latest analyst ratings for TMDX.

What is the current price target for TransMedics Group?

7 Wall Street analysts have set twelve-month price targets for TransMedics Group in the last year. Their average twelve-month price target is $53.29, suggesting a possible downside of 22.9%. Cowen Inc has the highest price target set, predicting TMDX will reach $70.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $39.00 for TransMedics Group in the next year.
View the latest price targets for TMDX.

What is the current consensus analyst rating for TransMedics Group?

TransMedics Group currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TMDX will outperform the market and that investors should add to their positions of TransMedics Group.
View the latest ratings for TMDX.

What other companies compete with TransMedics Group?

Other companies that are similar to TransMedics Group include InMode, Outset Medical, CONMED, LivaNova and BioLife Solutions. Learn More about companies similar to TransMedics Group.

How do I contact TransMedics Group's investor relations team?

TransMedics Group's physical mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company's listed phone number is (978) 552-0900 and its investor relations email address is [email protected] The official website for TransMedics Group is www.transmedics.com. Learn More about contacing TransMedics Group investor relations.